Expression Pathology Inc. (EPI) is a private biotechnology company leading
the development of innovative tissue protein analysis methods for
research and diagnostic applications.
The company’s proprietary “tissue microproteomics” technologies
have already been adopted by major academic and industrial researchers
worldwide, enabling discovery and analysis of protein biomarkers in tissue
employing the latest advances in mass spectrometry. Formalin-fixed and
paraffin-embedded (FFPE) tissue samples are routinely collected, tested
and archived in medical treatment and research facilities. They constitute
a huge untapped resource for discovery, validation and accurate measurement
of biomarkers of disease progression and recurrence, drug response and
toxicity. Expression Pathology’s Liquid
Tissue® sample preparation
and Director™ laser microdissection technologies are opening
new ways to extract valuable protein information from FFPE tissue.
EPI
is also using its technologies to develop proprietary new
cancer tests, both novel protein biomarkers to aid prognosis
and treatment decisions
and an accurate mass spectrometry-based alternative to current
qualitative methods for measuring proteins in tissue.
Expression
Pathology Inc. (EPI) is a leader in tissue
microproteomics. Our technologies make possible mass
spec protein analysis of formalin-fixed tissue,
enabling discovery, validation and routine
measurement of protein biomarkers related to clinical
outcomes. Our near-term mission is
to offer breakthrough research tools and
collaborations to improve drug and diagnostic development
and for basic research. Our proprietary
technologies also provide the foundation
for a whole new platform of tissue diagnostic tests currently
under development.
The Liquid
Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures the entire protein
content. Mass spec friendly. Requires only 30,000 cells for multiple
mass spectrometry analyses.
The Director™ Laser Microdissection Slides
provide the fastest, easiest and most accurate way to collect specific
cellular features from tissue sections. Engineered for use with existing
Leica LMD and PALM Zeiss laser microdissection system.
Investors
We are seeking investments and collaboration opportunities.
For more information please contact our business development group.
email
b u s d e v @ e x p r e s s i o n p a t h o l o g y . c o m
(transcribe email address to standard format or click on the
link. Spam bots have made it impossible to post properly formatted
email addresses.
